Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426891 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03426891 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 21 participants.
The verdict
NCT03426891, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety and tolerability of the combination treatment of the investigational drugs vorinostat and pembrolizumab, in combination with chemotherapy (temozolomide), and radiotherapy. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for use to treat a deadly skin cancer called melanoma and lung cancer and vorinostat to treat some forms of blood and lymph node cancers. However, both vorinostat and pembrolizumab are considered investigational drugs in this study because they are not approved for treatment of glioblastoma.
Interventions
- DRUG Pembrolizumab
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-03-16 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03426891
The ClinicalTrials.gov registry entry for NCT03426891 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03426891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03426891 about?
NCT03426891 is a clinical study titled "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma". The purpose of this research study is to test the safety and tolerability of the combination treatment of the investigational drugs vorinostat and pembrolizumab, in combination with chemotherapy (temozolomide), and radiotherapy. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab ...
What is the current status of trial NCT03426891?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-03-16. Estimated completion is 2023-06-28.
What interventions are being tested in trial NCT03426891?
The interventions under investigation include: Pembrolizumab (DRUG), Temozolomide (DRUG), Radiotherapy (RADIATION), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT03426891?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.